What is the projected market valuation of the Cryptococcosis Market by 2035?

The projected market valuation of the Cryptococcosis Market is expected to reach 3.088 USD Billion by 2035. Read More

What was the market valuation of the Cryptococcosis Market in 2024?

The market valuation of the Cryptococcosis Market was 0.67 USD Billion in 2024. Read More

What is the expected CAGR for the Cryptococcosis Market during the forecast period 2025 - 2035?

The expected CAGR for the Cryptococcosis Market during the forecast period 2025 - 2035 is 14.9%. Read More

Which companies are considered key players in the Cryptococcosis Market?

Key players in the Cryptococcosis Market include Gilead Sciences, Astellas Pharma, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, Sanofi, AbbVie, and Amgen. Read More

How much is the Cryptococcal Meningitis segment valued at in 2025?

The Cryptococcal Meningitis segment is valued at approximately 1.15 USD Billion in 2025. Read More

What is the projected value of the Molecular Testing segment by 2035?

The projected value of the Molecular Testing segment is expected to reach 0.75 USD Billion by 2035. Read More

What treatment types are available for Cryptococcosis?

Available treatment types for Cryptococcosis include Amphotericin B-based Regimens, Fluconazole, Combination Therapy, and Surgery. Read More

What is the expected market value for the Severe disease severity segment in 2025?

The expected market value for the Severe disease severity segment is approximately 1.288 USD Billion in 2025. Read More

Cryptococcosis Market

Q: What are the main segments of the Cryptococcosis Market based on infection type?

The main segments based on infection type include Cryptococcal Meningitis, Cryptococcal Pneumonia, Cryptococcal Urinary Tract Infection, and Other Cryptococcal Infections. Read More

Q: What diagnostic methods are utilized in the Cryptococcosis Market?

Diagnostic methods in the Cryptococcosis Market include Cryptococcal Antigen Testing, Cryptococcal Culture, India Ink Preparation, Molecular Testing, and Immunohistochemistry. Read More

ID: MRFR/Pharma/7782-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

Cryptococcosis Market Research Report By Infection Type (Cryptococcal Meningitis, Cryptococcal Pneumonia, Cryptococcal Urinary Tract Infection, Other Cryptococcal Infections), By Diagnostic Method (Cryptococcal Antigen Testing, Cryptococcal Culture, India Ink Preparation, Molecular Testing, Immunohistochemistry), By Treatment Type (Amphotericin B-based Regimens, Fluconazole, Combination Therapy, Surgery), By Disease Severity (Mild, Moderate, Severe), By End Use (Hospital, Ambulatory Care Centers, Research Laboratories) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Infection Type (USD Billion)
  1. 4.1.1 Cryptococcal Meningitis
  2. 4.1.2 Cryptococcal Pneumonia
  3. 4.1.3 Cryptococcal Urinary Tract Infection
  4. 4.1.4 Other Cryptococcal Infections
2. 4.2 Healthcare, BY Diagnostic Method (USD Billion)
  1. 4.2.1 Cryptococcal Antigen Testing
  2. 4.2.2 Cryptococcal Culture
  3. 4.2.3 India Ink Preparation
  4. 4.2.4 Molecular Testing
  5. 4.2.5 Immunohistochemistry
3. 4.3 Healthcare, BY Treatment Type (USD Billion)
  1. 4.3.1 Amphotericin B-based Regimens
  2. 4.3.2 Fluconazole
  3. 4.3.3 Combination Therapy
  4. 4.3.4 Surgery
4. 4.4 Healthcare, BY Disease Severity (USD Billion)
  1. 4.4.1 Mild
  2. 4.4.2 Moderate
  3. 4.4.3 Severe
5. 4.5 Healthcare, BY End Use (USD Billion)
  1. 4.5.1 Hospital
  2. 4.5.2 Ambulatory Care Centers
  3. 4.5.3 Research Laboratories
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Astellas Pharma (JP)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY INFECTION TYPE
4. 6.4 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
5. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE
6. 6.6 US MARKET ANALYSIS BY DISEASE SEVERITY
7. 6.7 US MARKET ANALYSIS BY END USE
8. 6.8 CANADA MARKET ANALYSIS BY INFECTION TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD
10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT TYPE
11. 6.11 CANADA MARKET ANALYSIS BY DISEASE SEVERITY
12. 6.12 CANADA MARKET ANALYSIS BY END USE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY INFECTION TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD
16. 6.16 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
17. 6.17 GERMANY MARKET ANALYSIS BY DISEASE SEVERITY
18. 6.18 GERMANY MARKET ANALYSIS BY END USE
19. 6.19 UK MARKET ANALYSIS BY INFECTION TYPE
20. 6.20 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD
21. 6.21 UK MARKET ANALYSIS BY TREATMENT TYPE
22. 6.22 UK MARKET ANALYSIS BY DISEASE SEVERITY
23. 6.23 UK MARKET ANALYSIS BY END USE
24. 6.24 FRANCE MARKET ANALYSIS BY INFECTION TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD
26. 6.26 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
27. 6.27 FRANCE MARKET ANALYSIS BY DISEASE SEVERITY
28. 6.28 FRANCE MARKET ANALYSIS BY END USE
29. 6.29 RUSSIA MARKET ANALYSIS BY INFECTION TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
31. 6.31 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
32. 6.32 RUSSIA MARKET ANALYSIS BY DISEASE SEVERITY
33. 6.33 RUSSIA MARKET ANALYSIS BY END USE
34. 6.34 ITALY MARKET ANALYSIS BY INFECTION TYPE
35. 6.35 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD
36. 6.36 ITALY MARKET ANALYSIS BY TREATMENT TYPE
37. 6.37 ITALY MARKET ANALYSIS BY DISEASE SEVERITY
38. 6.38 ITALY MARKET ANALYSIS BY END USE
39. 6.39 SPAIN MARKET ANALYSIS BY INFECTION TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD
41. 6.41 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
42. 6.42 SPAIN MARKET ANALYSIS BY DISEASE SEVERITY
43. 6.43 SPAIN MARKET ANALYSIS BY END USE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY INFECTION TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISEASE SEVERITY
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END USE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY INFECTION TYPE
51. 6.51 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
52. 6.52 CHINA MARKET ANALYSIS BY TREATMENT TYPE
53. 6.53 CHINA MARKET ANALYSIS BY DISEASE SEVERITY
54. 6.54 CHINA MARKET ANALYSIS BY END USE
55. 6.55 INDIA MARKET ANALYSIS BY INFECTION TYPE
56. 6.56 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
57. 6.57 INDIA MARKET ANALYSIS BY TREATMENT TYPE
58. 6.58 INDIA MARKET ANALYSIS BY DISEASE SEVERITY
59. 6.59 INDIA MARKET ANALYSIS BY END USE
60. 6.60 JAPAN MARKET ANALYSIS BY INFECTION TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD
62. 6.62 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
63. 6.63 JAPAN MARKET ANALYSIS BY DISEASE SEVERITY
64. 6.64 JAPAN MARKET ANALYSIS BY END USE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY INFECTION TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISEASE SEVERITY
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END USE
70. 6.70 MALAYSIA MARKET ANALYSIS BY INFECTION TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
72. 6.72 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
73. 6.73 MALAYSIA MARKET ANALYSIS BY DISEASE SEVERITY
74. 6.74 MALAYSIA MARKET ANALYSIS BY END USE
75. 6.75 THAILAND MARKET ANALYSIS BY INFECTION TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD
77. 6.77 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
78. 6.78 THAILAND MARKET ANALYSIS BY DISEASE SEVERITY
79. 6.79 THAILAND MARKET ANALYSIS BY END USE
80. 6.80 INDONESIA MARKET ANALYSIS BY INFECTION TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
82. 6.82 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
83. 6.83 INDONESIA MARKET ANALYSIS BY DISEASE SEVERITY
84. 6.84 INDONESIA MARKET ANALYSIS BY END USE
85. 6.85 REST OF APAC MARKET ANALYSIS BY INFECTION TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD
87. 6.87 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
88. 6.88 REST OF APAC MARKET ANALYSIS BY DISEASE SEVERITY
89. 6.89 REST OF APAC MARKET ANALYSIS BY END USE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY INFECTION TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD
93. 6.93 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
94. 6.94 BRAZIL MARKET ANALYSIS BY DISEASE SEVERITY
95. 6.95 BRAZIL MARKET ANALYSIS BY END USE
96. 6.96 MEXICO MARKET ANALYSIS BY INFECTION TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD
98. 6.98 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
99. 6.99 MEXICO MARKET ANALYSIS BY DISEASE SEVERITY
100. 6.100 MEXICO MARKET ANALYSIS BY END USE
101. 6.101 ARGENTINA MARKET ANALYSIS BY INFECTION TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
103. 6.103 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
104. 6.104 ARGENTINA MARKET ANALYSIS BY DISEASE SEVERITY
105. 6.105 ARGENTINA MARKET ANALYSIS BY END USE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY INFECTION TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE SEVERITY
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY INFECTION TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISEASE SEVERITY
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY INFECTION TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISEASE SEVERITY
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USE
122. 6.122 REST OF MEA MARKET ANALYSIS BY INFECTION TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD
124. 6.124 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
125. 6.125 REST OF MEA MARKET ANALYSIS BY DISEASE SEVERITY
126. 6.126 REST OF MEA MARKET ANALYSIS BY END USE
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY INFECTION TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY INFECTION TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DISEASE SEVERITY, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DISEASE SEVERITY, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY END USE, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.2.5 BY END USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.3.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.3.5 BY END USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.4.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.4.5 BY END USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.5.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.5.5 BY END USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.6.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.6.5 BY END USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.7.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.7.5 BY END USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.8.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.8.5 BY END USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.9.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.9.5 BY END USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.10.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.10.5 BY END USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.11.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.11.5 BY END USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.12.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.12.5 BY END USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.13.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.13.5 BY END USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.14.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.14.5 BY END USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.15.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.15.5 BY END USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.16.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.16.5 BY END USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.17.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.17.5 BY END USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.18.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.18.5 BY END USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.19.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.19.5 BY END USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.20.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.20.5 BY END USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.21.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.21.5 BY END USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.22.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.22.5 BY END USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.23.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.23.5 BY END USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.24.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.24.5 BY END USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.25.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.25.5 BY END USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.26.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.26.5 BY END USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.27.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.27.5 BY END USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.28.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.28.5 BY END USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.29.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.29.5 BY END USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY INFECTION TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.30.4 BY DISEASE SEVERITY, 2025-2035 (USD Billion)
  5. 7.30.5 BY END USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Cryptococcosis Market Segmentation

Cryptococcosis Market By Infection Type (USD Billion, 2025-2035)

Cryptococcal Meningitis
Cryptococcal Pneumonia
Cryptococcal Urinary Tract Infection
Other Cryptococcal Infections

Cryptococcosis Market By Diagnostic Method (USD Billion, 2025-2035)

Cryptococcal Antigen Testing
Cryptococcal Culture
India Ink Preparation
Molecular Testing
Immunohistochemistry

Cryptococcosis Market By Treatment Type (USD Billion, 2025-2035)

Amphotericin B-based Regimens
Fluconazole
Combination Therapy
Surgery

Cryptococcosis Market By Disease Severity (USD Billion, 2025-2035)

Mild
Moderate
Severe

Cryptococcosis Market By End Use (USD Billion, 2025-2035)

Hospital
Ambulatory Care Centers
Research Laboratories

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”